Savara Inc Deferred Tax Assets, Operating Loss Carryforwards
Savara Inc (SVRA) had Deferred Tax Assets, Operating Loss Carryforwards of $85.64 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-13
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $85.64M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $58.38M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $44.73M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $38.97M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $85.64M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $58.38M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $44.73M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $38.97M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $36.30M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $38.26M 10-K · filed 2022-03-30 | |
| 2019-12-31 | $30.95M 10-K · filed 2021-03-10 | |
| 2018-12-31 | $21.41M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $13.19M 10-K · filed 2019-03-13 | |
| 2016-12-31 | $7.48M 10-K · filed 2018-03-14 | $42.49M 10-K · filed 2017-03-06 |
| 2015-12-31 | $31.65M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $20.58M 10-K · filed 2016-03-14 | |
| 2013-12-31 | $12.99M 10-K · filed 2015-03-24 | $12.99M 10-K · filed 2014-03-26 |
| 2012-12-31 | $6.10M 10-K · filed 2014-03-26 | |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-06 | |
| 2011-12-31 | $17.79M 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |